Key Takeaways
- Moderna has initiated a late‑stage (Phase 3) clinical trial of its experimental mRNA bird‑flu vaccine, mRNA‑1018, in the United States and the United Kingdom.
- The study will enroll roughly 4,000 healthy adults aged 18 years and older and is supported by a $54 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI).
- This marks the first time an mRNA‑based pandemic influenza vaccine has reached late‑stage testing, highlighting the platform’s potential for rapid response to emerging viral threats.
- Moderna CEO Stéphane Bancel emphasized that avian influenza remains a serious pandemic risk and that the trial advances global preparedness efforts.
- Positive results from Moderna’s seasonal‑flu mRNA candidate, mRNA‑1010, could bolster any future regulatory filing for mRNA‑1018.
- Under its CEPI agreement, Moderna pledged to reserve 20 %)"}]} of its manufacturing capacity for affordable supply to low‑ and middle‑income countries if the vaccine is approved and a flu pandemic is declared.
- The trial follows a controversial decision by former U.S. Health Secretary Robert F. Kennedy Jr. to cancel over $700 million in Moderna bird‑flu vaccine contracts in May 2025, a move that CEPI’s December investment helps to offset.
- The mRNA technology, proven in COVID‑19 vaccines, enables faster design and production compared with traditional egg‑based influenza vaccines.
- Successful completion of the trial could provide a critical tool for mitigating the impact of a future avian‑influenza pandemic, especially in resource‑limited settings.
- The development underscores the growing role of public‑private partnerships in strengthening global vaccine readiness against epidemic and pandemic threats.
Background on Moderna’s mRNA‑1018 Vaccine
Moderna’s experimental vaccine, designated mRNA‑1018, employs the same messenger RNA platform that powered its COVID‑19 shots. Rather than using inactivated virus or proteins grown in eggs, mRNA‑1018 delivers genetic instructions that teach human cells to produce a specific avian influenza antigen, prompting an immune response. This approach allows the vaccine sequence to be redesigned quickly as new viral strains emerge, a key advantage for pandemic preparedness. The vaccine targets the hemagglutinin protein of highly pathogenic H5N1 avian influenza, a subtype that has caused sporadic human infections and raises concerns about sustained human‑to‑human transmission.
Details of the Late‑Stage Clinical Trial
The Phase 3 study announced on April 21 will enroll approximately 4,000 healthy adults aged 18 and above across trial sites in the United States and the United Kingdom. Participants will receive either the investigational mRNA‑1018 vaccine or a placebo, with the primary endpoints focusing on safety, immunogenicity, and efficacy against laboratory‑confirmed influenza illness caused by matching strains. Secondary objectives will assess durability of the immune response and any potential cross‑protection against drifted variants. The trial’s size and geographic spread aim to generate robust data suitable for regulatory submission to agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Funding and Support from CEPI
CEPI’s $54 million investment underpins the trial, reflecting the organization’s mission to accelerate vaccine development for epidemic and pandemic threats. CEPI, a global partnership founded in 2017, pools resources from governments, philanthropies, and the private sector to de‑risk early‑stage vaccine candidates. The funding covers clinical‑trial expenses, manufacturing of trial material, and related regulatory activities. CEPI’s involvement also signals confidence in Moderna’s mRNA platform as a viable tool for rapid pandemic response, a view reinforced by the success of mRNA vaccines during the COVID‑19 pandemic.
Context of Prior U.S. Government Contract Cancellations
In May 2025, then‑U.S. Health Secretary Robert F. Kennedy Jr. announced the cancellation of more than $700 million in contracts with Moderna aimed at developing a bird‑flu vaccine. The decision sparked debate among public‑health experts, who warned that abandoning prepandemic investments could weaken national readiness. CEPI’s December investment partially mitigates the financial gap left by those cancellations, allowing Moderna to advance mRNA‑1018 into late‑stage testing despite the federal pullback. The episode highlights the volatility of public‑policy support for pandemic preparedness and the importance of alternative funding mechanisms.
Advantages of mRNA Technology for Influenza Vaccines
Traditional influenza vaccines are predominantly produced in fertilized chicken eggs, a process that can take six months or longer and is vulnerable to supply disruptions. mRNA vaccines, by contrast, can be designed digitally once the viral genetic sequence is known, with manufacturing timelines measured in weeks. This speed enables a quicker match to circulating strains and facilitates rapid scale‑up during an outbreak. Moreover, mRNA platforms induce both humoral and cellular immunity, potentially offering broader protection against antigenically diverse viruses. Moderna’s experience with COVID‑19 mRNA vaccines has demonstrated the platform’s scalability, safety, and efficacy, providing a strong foundation for advancing mRNA‑1018.
Leadership Perspective on Pandemic Threats
Moderna Chief Executive Stéphane Bancel underscored that avian influenza remains a credible pandemic threat, citing recent sporadic human cases and the virus’s ability to undergo genetic reassortment. He characterized the initiation of the mRNA‑1018 trial as an important step toward bolstering global preparedness, noting that lessons learned from COVID‑19 vaccine deployment can be applied to influenza. Bancel also stressed the value of collaborative frameworks like CEPI, which align industry incentives with public‑health goals and ensure that breakthroughs reach populations most in need.
Linkage to Seasonal Flu Vaccine Candidate mRNA‑1010
Moderna indicated that any future regulatory filing for mRNA‑1018 would be bolstered by positive data from its separate seasonal‑influenza mRNA candidate, mRNA‑1010. That vaccine, which targets the four strains recommended for the annual flu vaccine, is currently under review in the United States, the European Union, Canada, and Australia. Success with mRNA‑1010 could facilitate a faster review pathway for mRNA‑1018 by establishing a precedent for safety and effectiveness of Moderna’s mRNA influenza platform, thereby reducing regulatory uncertainty for the pandemic‑focused product.
Manufacturing Commitments for Equitable Access
Under the terms of its agreement with CEPI, Moderna pledged that, should mRNA‑1018 receive regulatory approval and a flu pandemic be declared, it will allocate 20 % of its global manufacturing capacity to supply the vaccine at affordable prices to low‑ and middle‑income countries. This commitment reflects a growing emphasis on equity in pandemic response, aiming to prevent vaccine hoarding and ensure that vulnerable populations can access protective measures promptly. The pledge also aligns with CEPI’s broader objective of fostering fair distribution of vaccines developed with its support.
Implications for Global Pandemic Preparedness
The launch of the mRNA‑1018 late‑stage trial represents a tangible advancement in the world’s arsenal against potential avian‑influenza pandemics. By leveraging the speed and adaptability of mRNA technology, backed by CEPI funding and reinforced by data from a seasonal‑flu counterpart, Moderna is positioning itself to deliver a timely vaccine should an outbreak occur. The trial’s outcomes will inform not only Moderna’s regulatory strategy but also broader public‑health policies concerning vaccine stockpiling, manufacturing surge capacity, and international equity agreements. As the scientific community continues to monitor zoonotic influenza threats, initiatives like this one underscore the necessity of sustained investment, cross‑sector collaboration, and innovative platforms to safeguard global health.